APA (7th ed.) Citation

JH, C., & BA, D. (2025). Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy. Drugs, 85(10), 1231. https://doi.org/10.1007/s40265-025-02232-7

Chicago Style (17th ed.) Citation

JH, Cooperrider, and Derman BA. "Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy." Drugs 85, no. 10 (2025): 1231. https://doi.org/10.1007/s40265-025-02232-7.

MLA (9th ed.) Citation

JH, Cooperrider, and Derman BA. "Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy." Drugs, vol. 85, no. 10, 2025, p. 1231, https://doi.org/10.1007/s40265-025-02232-7.